`
`IN THE UNITED STATES PATENT AND TRADEMARKOFFICE
`
`IN RE: Cummings, S. et al.
`
`GROUP ARTUNIT: 1645
`
`SERIAL NO.: 15/755721
`
`CONFIRMATION NO: 5365
`
`FILING DATE: February 27, 2018
`
`EXAMINER: BASKAR, Padmavathi
`
`PATENT NO.: 10,634,675
`
`ISSUE DATE: April 28, 2020
`
`TITLE: COMPOSITIONS AND METHODS FOR PROTEIN DETECTION
`
`REQUEST FOR CERTIFICATE OF CORRECTION
`
`DATE: April 7, 2021
`
`Commissioner for Patents
`Office of Data ManagementAttention: Certificate of Correction Branch
`P.O. Box 1450
`
`Alexandria, VA 22313-1450
`
`Dear Commissioner:
`
`Patentee requests a Certificate of Correction, pursuant to 37 C.F.R. §1.323, be
`
`issued to correct the error indicated on the enclosed Form PTO/SB/44 for U.S. Patent
`
`10,634,675. This error is clerical
`
`in nature and does not constitute new matter or
`
`require reexamination.
`
`As this error contains both a mistake of the USPTO (mistakenly putting the
`
`number “13” instead of “9”) and a mistake of Patentee (omitting the word “claim’),
`
`Patentee is submitting the fee set forth in 37 C.F.R. § 1.20(a).
`
`CUSTOMER NO. 22847
`
`Respectfully submitted by,
`
`/Amy Krom/
`
`Krom, Amy
`Attorney for Applicants
`Reg. No. 73,073
`Phone: 919-226-7355
`
`
`
`PATENTNO.
`
`: 10,634,675
`
`APPLICATION NO.: 15/755721
`
`ISSUE DATE
`
`: April 28, 2020
`
`INVENTOR(S)
`
`Simone Cummings, Julie Smith, Magda Foege
`
`It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent
`is hereby corrected as shown below:
`
`In claim 10 at column 58, lines 53-54, the phrase "The monoclonal antibody of 13 that is HO4Mab70 antibody."
`
`PTO/SB/44 (09-07)
`Approved for use through 03/31/2023. OMB 0651-0033
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`Also Form PTO-1050
`
`UNITED STATES PATENT AND TRADEMARKOFFICE
`CERTIFICATE OF CORRECTION
`
`should read --The monoclonal antibody of claim 9 that is HO4Mab70 antibody.--
`
`MAILING ADDRESS OF SENDER(Please do not use Customer Number below):
`
`Amy Krom c/o Syngenta Crop Protection LLC
`9 Davis Drive
`Research Triangle Park, NC 27709
`This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public whichis tofile
`(and by the USPTOto process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any
`comments on the amountof time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer,
`U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED
`FORMSTO THIS ADDRESS. SEND TO:Attention Certificate of Corrections Branch, Commissionerfor Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.
`
`
`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection
`with your submission of the attached form related to a patent application or patent. Accordingly,
`pursuant to the requirements of the Act, please be advised that: (1) the general authority for the
`collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information Solicited is voluntary;
`and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark
`Office is to process and/or examine your Submission related to a patent application or patent. If you do
`not furnish the requested information, the U.S. Patent and Trademark Office may not be able to
`process and/or examine your submission, which may result in termination of proceedings or
`abandonmentof the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed under the
`Freedom ofInformation Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from
`this system of records maybe disclosed to the Department of Justice to determine whether
`disclosure of these records is required by the Freedom ofInformation Act.
`A record from this system of records may be disclosed, as a routine use, in the course of
`presenting evidenceto a court, magistrate, or administrative tribunal, including disclosures to
`opposing counsel in the course of settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Member of
`Congress submitting a request involving an individual, to whom the record pertains, when the
`individual has requested assistance from the Member with respect to the subject matter of the
`record.
`A record in this system of records may be disclosed, as a routine use, to a contractor of the
`Agency having needfor the information in order to perform a contract. Recipients of
`information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`A record related to an International Application filed under the Patent Cooperation Treaty in
`this system of records maybe disclosed, as a routine use, to the International Bureau of the
`World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal
`agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to
`the Atomic Energy Act (42 U.S.C. 218(c)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator,
`General Services, or his/her designee, during an inspection of records conducted by GSA as
`part of that agency’s responsibility to recommend improvements in records management
`practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall
`be made in accordance with the GSA regulations governing inspection of records for this
`purpose, and any other relevant (/.e., GSA or Commerce) directive. Such disclosure shall not
`be used to make determinations aboutindividuals.
`A record from this system of records may be disclosed, as a routine use, to the public after
`either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent
`pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, aS a routine use, to the public if the record wasfiled in an application which
`became abandonedor in which the proceedings were terminated and which application is
`referenced byeither a published application, an application open to public inspection or an
`issued patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State,
`or local law enforcement agency, if the USPTO becomesawareof a violation or potential
`violation of law or regulation.
`
`